{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"3.6","value":"2.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"Progression-free survival is the period from study entry until disease progression, death or date of last contact","dispersionType":"95% Confidence Interval","groups":[{"description":"Pazopanib 800mg daily until disease progression or adverse effects prohibit further therapy (one cycle equals 28 days)","id":"OG000","title":"Pazopanib"}],"paramType":"MEDIAN","populationDescription":"Eligible and Treated Patients","reportingStatus":"POSTED","timeFrame":"From start of treatment to time of progression or death, assessed up to 5 years","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}